Angiogenesis, the sprouting of new blood vessels from existing vessels, is one of six known
mechanisms employed by solid tumors to recruit blood vessels necessary for their initiation …

Introduction The vascular endothelial growth factor A (VEGF) is the main mediator of
angiogenesis. In addition, VEGF contributes to cancer growth and metastasis directly …

Introduction The treatment of patients with EGFR-mutant NSCLC with vascular endothelial
growth factor (VEGF) inhibitors in combination with EGFR inhibitors provides a greater …

Purpose: Resistance to VEGFR inhibitors is a major obstacle in the treatment of non–small
cell lung cancer (NSCLC). We investigated the cellular mechanisms mediating resistance of …

For years, the renin-angiotensin system (RAS) has been perceived as a system whose role
is to primarily modulate the functioning of the cardiovascular system. Years of research into …

Sorafenib is FDA-approved for the treatment of primary kidney or liver cancer, but its ability
to inhibit many types of kinases suggests it may have potential for treating other diseases …

Background Recent studies have identified that glioblastoma IDH-wildtype (GBM IDH-WT)
might be comprised of molecular subgroups with distinct prognoses. Therefore, we …

The chronic receipt of renin-angiotensin-aldosterone system (RAAS) inhibitors including
angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) …

Purpose Amplifications of receptor tyrosine kinases (RTKS) are therapeutic targets in
multiple tumor types (eg HER2 in breast cancer), and amplification of the chromosome 4 …

The regulation of muscle stem cell (MuSC) asymmetric division plays an essential role in
controlling the growth and repair of skeletal muscle. We discover kinase domain receptor …